ALZHEIMER’S DISEASE DIAGNOSTICS AND THERAPEUTICS MARKET ANALYSIS
Key players are focusing on providing new diagnostic tests which will drive the market growth during the forecast period. For instance, Attyloid GmbH, a biotechnology company, offers a biomarker-based laboratory test sFIDA (surface-based fluorescence intensity distribution analysis), for diagnosing Alzheimer’s disease. sFIDA can identify and quantify Aβ oligomers. These small protein aggregates play a significant role in the development and prognosis of Alzheimer’s disease. By sFIDA, differentiation between control samples and AD patient is easily possible.
Global Alzheimer’s disease Diagnostics and Therapeutics Market- Key Players
Major players operating in the global Alzheimer’s disease diagnostics and therapeutics market include Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc.
Alzheimer’s Disease Diagnostics and Therapeutics Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request DiscountPress Release
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :